<DOC>
	<DOCNO>NCT02970955</DOCNO>
	<brief_summary>Oligometastatic patient inoperable thoracic node metastasis primary , except hematologic malignancy , undergo risk adaptive scheme stereotactic body radiation therapy ( SBRT ) .</brief_summary>
	<brief_title>Prospecitve Observational Study Risk Adaptive Scheme SBRT Thoracic Nodes Metastases</brief_title>
	<detailed_description>The observational study design evaluate safety efficacy risk adaptive scheme stereotactic body radiation therapy ( SRT ) oligometastatic patient thoracic nodes metastasis , medically inoperable , use VMAT RapidArc approach . The potential advantage technique ability deliver selective irradiation tumour 's target reduce dos normal tissue , optimize therapeutic window .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients age &gt; 18 year ECOG 02 Karnofsky index &gt; 70 % ( ECOG &gt; 2 ) Any primary , except hematologic malignancy DFI ( Diseasefree interval ) diagnosis &gt; 6 month Unresectable lesion inoperable patient patient refuse surgery Less 3 metastatic thoracic nod No extrathoracic disease metastatic site stable respond chemotherapy , less 5 metastatic site No life threaten condition Chemotherapy complete least 1 week treatment Chemotherapy start least 1 week treatment allow Systemic therapy chemotherapy allow ( i.e hormonal therapy and/or immunotherapy ) Written inform consent Previous RT region Pregnant woman Patients inability consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>